ABSTRACT

Purpose:

To determine safety and visual outcomes in eyes with advanced age-related macular degeneration (AMD) implanted with a novel intraocular lens (IOL) that delivers an optimized retinal image to all macular areas within 10 degrees of retinal eccentricity.

Methods:

This was a consecutive case series of 11 eyes of 9 patients with advanced stage AMD. Eyemax monoTM (London Eye Hospital Pharma), a single-piece, injectable, hydrophobic acrylic IOL sited in the capsular bag was implanted in all eyes. Primary outcome was safety. Secondary outcome was change in corrected distance visual acuity (CDVA) (logMAR).

Results:

Mean age at surgery was 60 years. Mean duration of follow-up was 6 months. Causes of visual loss were geographic atrophy and macular scar due to AMD in 10 eyes, chronic central serous chorioretinopathy in one eye. No eyes had worsening of CDVA postoperatively. Perioperative complications were IOL exchange due to haptic break in two patients, and anterior capsular rupture during IOL insertion in one patient. Mean preoperative CDVA improved from 1.3 to 0.9 postoperatively, equating to an approximate Early Treatment Diabetic Retinopathy Study gain of 20 letters.

Conclusions:

This novel IOL appears safe in the short to medium term. Improvement in postoperative CDVA exceed those observed with standard implants in advanced AMD patients.


CONTACT DETAILS

Tansu ERAKGUN
Kaskaloglu Eye Hospital
Izmir
Turkey
Email : terakgun@hotmail.com
Cell Phone: +905323962620
Work Phone: +902324650505